Table 3.

HPV 9-valent vaccine immunogenicity findings of included studies

Study population	Analysis	HPV type	Immunogenicity comparison with qHPV vaccine
			Month 7 GMT ratio	Month 7 seroconversion % difference
Females, 16–26 years [34]*	Per-protocol	Anti-HPV-6	1·02 (0·99–1·06)	0·0 (−0·3 to 0·2)
		Anti-HPV-11	0·80 (0·77–0·83)	0·0 (−0·1 to 0·2)
		Anti-HPV-16	0·99 (0·96–1·03)	0·0 (−0·1 to 0·2)
		Anti-HPV-18	1·19 (1·14–1·23)	0·1 (−0·1 to 0·4)
Females, 9–15 years [43]		Anti-HPV-6	1·07 (0·93–1·23)
		Anti-HPV-11	0·93 (0·80–1·08)
		Anti-HPV-16	0·97 (0·85–1·11)*
		Anti-HPV-18	1·08 (0·91–1·29)*
Males, 16–26 years [41]*	Per-protocol	Anti-HPV-6	1·23 (1·04–1·45)	−0·5 (−0·6 to 0·2)
		Anti-HPV-11	0·89 (0·76–1·04)	0·0 (0–0)
		Anti-HPV-16	1·04 (0·89–1·21)	0·0 (−0·1 to 0)
		Anti-HPV-18	1·12 (0·91–1·37)	0·0 (−0·1 to 0)

qHPV, human papillomavirus quadrivalent vaccine; GMT, geometric mean titer.

^*The P value for non-inferiority was <0·001 for all comparisons HPV 9-valent vaccine vs. qHPV vaccine.